Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), focused on virus-associated malignancies, announced that CEO Dr. Ivor Royston will present at the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. The presentation is scheduled for March 16 at 2:30 p.m. ET. Investors can access the presentation via a provided webcast link. Viracta is currently evaluating its investigational drug, nanatinostat, in a Phase 2 trial for EBV-positive lymphoma. A replay of the presentation will be available for 90 days on the company's website.
- None.
- None.
SAN DIEGO, March 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of Viracta will present at the Oppenheimer 31st Annual Healthcare Conference taking place virtually from March 16-18, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.
Presentation details can be found below.
Date: | Tuesday, March 16, 2021 |
Time: | 2:30 p.m. ET |
Webcast Link: |
A replay of the presentation will be archived for 90 days on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact: | Company Contact: |
Joyce Allaire | Dan Chevallard |
LifeSci Advisors | Chief Operating Officer and Chief Financial Officer |
(212) 915-2569 | (858) 771-4193 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301245295.html
SOURCE Viracta
FAQ
When will Viracta present at the Oppenheimer Healthcare Conference?
How can I watch the Viracta presentation at the conference?
What is the focus of Viracta Therapeutics?
What clinical trial is Viracta currently involved in?
Where can I find a replay of Viracta's presentation?
